There has been substantial progress over the last decade in understanding the origins and inflammatory progressions of psoriatic arthritis (PsA), which has led to the development of improved pharmacologic agents. While there are now a wide variety of biologics, biosimilars, and targeted treatments available, several novel agents are currently in late-stage trials and have the potential to dramatically improve care. “Comprehending the PsA Agents in Late-Stage Clinical Development” will review relevant clinical trial data and explore all the potential uses of novel investigational therapies for PsA.